砷剂联合全反式维甲酸治疗儿童急性早幼粒细胞白血病:CCLG-APL2016研究
该多中心研究在中国38家医院纳入193例初诊儿童急性早幼粒细胞白血病患者,按基线白细胞计数和FLT3-ITD突变分层,标准风险组接受全反式维甲酸联合砷剂(三氧化二砷或口服砷)不联合化疗,高风险组加用减量蒽环类。中位随访28.9个月,2年总生存率标准风险组99%、高风险组95%,2年无事件生存率分别为97%和90%。结论认为砷剂联合全反式维甲酸在儿童APL中有效且安全,但需长期随访。
要点
- 标准风险组2年总生存率99%,高风险组95%。
- 标准风险组2年无事件生存率97%,高风险组90%。
- 治疗期间血浆砷有效浓度稳定在42.9-63.2 ng/mL。
核心结论
- 砷剂联合全反式维甲酸在儿童急性早幼粒细胞白血病中有效且安全,但仍需长期随访。
研究设计与样本
- 中国38家医院开展的多中心试验,纳入193例初诊儿童急性早幼粒细胞白血病患者。
- 按基线白细胞计数和FLT3-ITD突变分为标准风险组和高风险组。
- 标准风险组接受全反式维甲酸联合三氧化二砷或口服砷,不联合化疗;高风险组加用减量蒽环类。
- 主要终点为2年无事件生存率和总生存率。
主要发现
- 治疗后血浆砷水平显著升高,治疗期间稳定有效浓度范围为42.9-63.2 ng/mL。
- 治疗结束后6个月,血浆、尿液、头发和指甲砷水平迅速降至正常。
临床怎么用
- 儿童APL可考虑采用砷剂联合全反式维甲酸治疗,标准风险组免化疗,高风险组加用减量蒽环类。
- 治疗期间血浆砷有效浓度可维持在42.9-63.2 ng/mL,停药6个月后各组织砷水平恢复正常。
局限性
- 仍需长期随访以评估远期安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Arsenic combined with all-trans retinoic acid (ATRA) is the standard of care for adult acute promyelocytic leukemia (APL). However, the safety and effectiveness of this treatment in pediatric patients with APL have not been reported on the basis of larger sample sizes. METHODS: We conducted a multicenter trial at 38 hospitals in China. Patients with newly diagnosed APL were stratified into two risk groups according to baseline WBC count and FLT3-ITD mutation. ATRA plus arsenic trioxide or oral arsenic without chemotherapy were administered to the standard-risk group, whereas ATRA, arsenic trioxide, or oral arsenic plus reduced-dose anthracycline were administered to the high-risk group. Primary end points were event-free survival and overall survival at 2 years. RESULTS: We enrolled 193 patients with APL. After a median follow-up of 28.9 months, the 2-year overall survival rate was 99% (95% CI, 97 to 100) in the standard-risk group and 95% (95% CI, 90 to 100) in the high-risk group (P = .088). The 2-year event-free survival was 97% (95% CI, 93 to 100) in the standard-risk group and 90% (95% CI, 83 to 96) in the high-risk group (P = .252). The plasma levels of arsenic were significantly elevated after treatment, with a stable effective level ranging from 42.9 to 63.2 ng/mL during treatment. In addition, plasma, urine, hair, and nail arsenic levels rapidly decreased to normal 6 months after the end of treatment. CONCLUSION: Arsenic combined with ATRA is effective and safe in pediatric patients with APL, although long-term follow-up is still needed.
引用
- Zheng H, Jiang H, Hu S, et al. Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study. J Clin Oncol. 2021. PMID: 34077242. doi:10.1200/JCO.20.03096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。